Literature DB >> 30923938

Pharmacokinetic correlates of venlafaxine: associated adverse reactions.

Georgios Schoretsanitis1, Ekkehard Haen2,3, Christoph Hiemke4, Katharina Endres2,3, Florian Ridders2,3, Tanja Veselinovic5,6, Gerhard Gründer7, Michael Paulzen5,6,8.   

Abstract

To address the potential correlation between plasma concentrations of venlafaxine (VEN), its active metabolite O-desmethylvenlafaxine (ODVEN) and the active moiety, AM, (ODVEN + VEN) and adverse drug reactions (ADR) in a large naturalistic sample of in- and outpatients. We compared plasma concentrations of VEN, ODVEN and AM and dose-adjusted (C/D) levels as well the ODVEN/VEN ratios between patients complaining ADRs, following the Udvalg for Kliniske Undersogelser side effect rating scales (UKU) (n = 114) and patients without ADRs (control group, n = 688) out of a naturalistic database. We also investigated potential pharmacokinetic correlates of the four UKU categories by comparing patients complaining ADRs with those who did not. Based on previous literature we applied different ODVEN/VEN ratio values as cut-offs to split our sample into two groups at a time and compare frequencies of ADRs between the groups. No differences for demographic and pharmacokinetic variables including plasma and C/D concentrations as well as ODVEN/VEN ratios were observed between study groups. Neither the comparisons between females and males nor between elderly and non-elderly patients revealed significant differences (p > 0.05 in all cases). No differences were also reported exploring the patients complaining ADRs from the 4 UKU categories separately. After applying various ODVEN/VEN cut-offs, groups did not display differences in frequencies of ADRs (p > 0.05 in all cases). Our findings do not demonstrate a direct link between venlafaxine metabolism measures and ADRs. Therefore, additional dimensions are needed to be considered in future trials aiming to disentangle the involved aspects of ADRs in patients receiving venlafaxine.

Entities:  

Keywords:  Adverse drug reactions; Antidepressants; Drug metabolism; Pharmacokinetics; Psychopharmacology

Mesh:

Substances:

Year:  2019        PMID: 30923938     DOI: 10.1007/s00406-019-01005-0

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  2 in total

1.  In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine.

Authors:  Feifei Chen; Hui Jiang; Jia Xu; Shuanghu Wang; Deru Meng; Peiwu Geng; Dapeng Dai; Quan Zhou; Yunfang Zhou
Journal:  Drug Des Devel Ther       Date:  2020-11-10       Impact factor: 4.162

2.  Early intervention of acute liver injury related to venlafaxine: A case report.

Authors:  Lin Fang; Shushan Wang; Leiming Cao; Kun Yao
Journal:  Medicine (Baltimore)       Date:  2021-12-10       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.